Drug · DIN 02449781
NUCALA
100 MG/ML RECONSTITUTED, SINGLE-USE VIAL, LYOPHILIZED POWDER
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 6, 2023; first marketed March 14, 2016.
- Drug Identification Number (DIN)
- 02449781
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Powder For Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Mepolizumab R03DX09
- Class
- Human
- Record last updated
- July 29, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MEPOLIZUMAB | 100 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 3, 2015: NOC 17548New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “nucala”. A notice may cover another product or only some lots: read it to see what it covers.
- NUCALA SAFETY SYRINGE(2021-07-09)July 9, 2021 · Drugs · Product safety · Type II
- NUCALA PRE-FILLED AUTOINJECTOR(2021-07-09)July 9, 2021 · Drugs · Product safety · Type II
Other DINs named NUCALA
- DIN 02492989 · Marketed
- DIN 02492997 · Marketed
- DIN 02530821 · Marketed